Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

No effect of triheptanoin on exercise performance in McArdle disease.

Madsen KL, Laforêt P, Buch AE, Stemmerik MG, Ottolenghi C, Hatem SN, Raaschou-Pedersen DT, Poulsen NS, Atencio M, Luton MP, Ceccaldi A, Haller RG, Quinlivan R, Mochel F, Vissing J.

Ann Clin Transl Neurol. 2019 Sep 14. doi: 10.1002/acn3.50863. [Epub ahead of print]

2.

Effect of changes in fat availability on exercise capacity in McArdle disease.

Andersen ST, Jeppesen TD, Taivassalo T, Sveen ML, Heinicke K, Haller RG, Vissing J.

Arch Neurol. 2009 Jun;66(6):762-6. doi: 10.1001/archneurol.2009.93.

PMID:
19506137
3.

Fat metabolism during exercise in patients with McArdle disease.

Ørngreen MC, Jeppesen TD, Andersen ST, Taivassalo T, Hauerslev S, Preisler N, Haller RG, van Hall G, Vissing J.

Neurology. 2009 Feb 24;72(8):718-24. doi: 10.1212/01.wnl.0000343002.74480.e4.

PMID:
19237700
4.

Lactate and Energy Metabolism During Exercise in Patients With Blocked Glycogenolysis (McArdle Disease).

Ørngreen MC, Jeppesen TD, Taivassalo T, Hauerslev S, Preisler N, Heinicke K, Haller RG, Vissing J, van Hall G.

J Clin Endocrinol Metab. 2015 Aug;100(8):E1096-104. doi: 10.1210/jc.2015-1339. Epub 2015 Jun 1.

PMID:
26030324
5.

Carbohydrate- and protein-rich diets in McArdle disease: effects on exercise capacity.

Andersen ST, Vissing J.

J Neurol Neurosurg Psychiatry. 2008 Dec;79(12):1359-63. doi: 10.1136/adc.2008.146548. Erratum in: J Neurol Neurosurg Psychiatry. 2010 Dec;81(12)1414.

PMID:
19010947
6.

Metabolic profiles of exercise in patients with McArdle disease or mitochondrial myopathy.

Delaney NF, Sharma R, Tadvalkar L, Clish CB, Haller RG, Mootha VK.

Proc Natl Acad Sci U S A. 2017 Aug 1;114(31):8402-8407. doi: 10.1073/pnas.1703338114. Epub 2017 Jul 17.

7.

Glutamate availability is important in intramuscular amino acid metabolism and TCA cycle intermediates but does not affect peak oxidative metabolism.

Mourtzakis M, Graham TE, González-Alonso J, Saltin B.

J Appl Physiol (1985). 2008 Aug;105(2):547-54. doi: 10.1152/japplphysiol.90394.2008. Epub 2008 May 29.

8.

Effect of triheptanoin on muscle metabolism during submaximal exercise in horses.

McCue ME, Valberg SJ, Pagan JD, Essén-Gustavsson B, Roe CR.

Am J Vet Res. 2009 Aug;70(8):1043-52. doi: 10.2460/ajvr.70.8.1043.

PMID:
19645587
9.

Effect of fuels on exercise capacity in muscle phosphoglycerate mutase deficiency.

Vissing J, Quistorff B, Haller RG.

Arch Neurol. 2005 Sep;62(9):1440-3.

PMID:
16157752
10.

UX007 for the treatment of long chain-fatty acid oxidation disorders: Safety and efficacy in children and adults following 24weeks of treatment.

Vockley J, Burton B, Berry GT, Longo N, Phillips J, Sanchez-Valle A, Tanpaiboon P, Grunewald S, Murphy E, Humphrey R, Mayhew J, Bowden A, Zhang L, Cataldo J, Marsden DL, Kakkis E.

Mol Genet Metab. 2017 Apr;120(4):370-377. doi: 10.1016/j.ymgme.2017.02.005. Epub 2017 Feb 7.

11.

Effect of high-dose creatine therapy on symptoms of exercise intolerance in McArdle disease: double-blind, placebo-controlled crossover study.

Vorgerd M, Zange J, Kley R, Grehl T, Hüsing A, Jäger M, Müller K, Schröder R, Mortier W, Fabian K, Malin JP, Luttmann A.

Arch Neurol. 2002 Jan;59(1):97-101.

PMID:
11790236
12.

Effect of oral sucrose shortly before exercise on work capacity in McArdle disease.

Andersen ST, Haller RG, Vissing J.

Arch Neurol. 2008 Jun;65(6):786-9. doi: 10.1001/archneur.65.6.786.

PMID:
18541798
13.

Splice mutations preserve myophosphorylase activity that ameliorates the phenotype in McArdle disease.

Vissing J, Duno M, Schwartz M, Haller RG.

Brain. 2009 Jun;132(Pt 6):1545-52. doi: 10.1093/brain/awp065. Epub 2009 May 11.

PMID:
19433441
14.
15.

Exercise with low muscle glycogen augments TCA cycle anaplerosis but impairs oxidative energy provision in humans.

Gibala MJ, Peirce N, Constantin-Teodosiu D, Greenhaff PL.

J Physiol. 2002 May 1;540(Pt 3):1079-86.

16.

The effect of a submaximal exercise orientation on cardiopulmonary cycle ergometer stress test results in older adults.

Shaw CE, McCully KK, Landsberg L, Posner J.

J Cardiopulm Rehabil. 1996 Mar-Apr;16(2):93-9.

PMID:
8681162
17.

Long-term major clinical outcomes in patients with long chain fatty acid oxidation disorders before and after transition to triheptanoin treatment--A retrospective chart review.

Vockley J, Marsden D, McCracken E, DeWard S, Barone A, Hsu K, Kakkis E.

Mol Genet Metab. 2015 Sep-Oct;116(1-2):53-60. doi: 10.1016/j.ymgme.2015.06.006. Epub 2015 Jun 18. Review. Erratum in: Mol Genet Metab. 2015 Nov;116(3):221.

18.

Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial.

Gillingham MB, Heitner SB, Martin J, Rose S, Goldstein A, El-Gharbawy AH, Deward S, Lasarev MR, Pollaro J, DeLany JP, Burchill LJ, Goodpaster B, Shoemaker J, Matern D, Harding CO, Vockley J.

J Inherit Metab Dis. 2017 Nov;40(6):831-843. doi: 10.1007/s10545-017-0085-8. Epub 2017 Sep 4.

19.

Gender differences in fat oxidation and sympathetic nervous system activity at rest and during submaximal exercise in older individuals.

Toth MJ, Gardner AW, Arciero PJ, Calles-Escandon J, Poehlman ET.

Clin Sci (Lond). 1998 Jul;95(1):59-66.

PMID:
9662486
20.

Impaired glycogen breakdown and synthesis in phosphoglucomutase 1 deficiency.

Preisler N, Cohen J, Vissing CR, Madsen KL, Heinicke K, Sharp LJ, Phillips L, Romain N, Park SY, Newby M, Wyrick P, Mancias P, Galbo H, Vissing J, Haller RG.

Mol Genet Metab. 2017 Nov;122(3):117-121. doi: 10.1016/j.ymgme.2017.08.007. Epub 2017 Aug 25.

PMID:
28882528

Supplemental Content

Support Center